Business
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine. \n\n \n \n \n \n \n \n\n \nThe trial is an open-label, multiple-ascending dose Phase 1a trial to evaluate safety and monitor immune response after vaccination. A critical goal was to determine the maximum tolerated dose of the vaccine. The MTD is the highest dose of a medicine or treatment that will produce the desired effect without resulting in unacceptable side effects. Higher concentrations may be effective but may induce side effects that deter use or outweigh the benefits of treatment. The MTD will guide dosing in successive Phase 2 and Phase 3 trials. Recently, a Phase 1b trial was commenced, based on the results to date of the Phase 1a trial. The Phase 1a and Phase 1b trials are currently being conducted at Cleveland Clinic and include women who have previously been diagnosed with triple negative breast cancer and are currently cancer free and at risk of recurrence, and healthy cancer free women at high risk for developing breast cancer in the future, respectively. Future trials are expected to be conducted at multiple sites. \n\"We are pleased to have reached this important milestone in the clinical development of our preventative breast cancer vaccine, and we look forward to completing enrollment for the Phase 1a trial,\" stated Dr. Amit Kumar, Chairman and CEO of Anixa. \"After the last participant is vaccinated and completes all follow up tests, we will compile and analyze the data. We look forward to presenting the complete immunological data from the trial at a scientific conference or similar setting in the second quarter of 2023.\"\nAbout Anixa Bioscience's Breast Cancer VaccineAnixa's breast cancer vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become \"retired\" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the...